Insider Monkey

Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development

Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc.
Nasdaq

Gain Therapeutics Appoints New CEO Amidst Clinical Progress

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Gain Therapeutics ( ...
ascopubs.org

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies

In 124 trials with low crossover, PFS half-life gain ≥1.5 months predicted OS gain ≥2 months (positive predictive value [PPV] 82%, negative predictive value [NPV] 86%). Higher PFS gains predicted ...
Nasdaq

Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development

Gain Therapeutics reports Q1 2025 financial results, progressing Phase 1b study of Parkinson's treatment GT-02287, with FDA engagement anticipated. Successful administration of GT-02287, a lead drug ...
ascopubs.org

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies The following represents disclosure information ...